Rnase L Manipulates Macrophages in Innate Immunity and Tumor Growth by Yi, Xin
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2012
Rnase L Manipulates Macrophages in Innate
Immunity and Tumor Growth
Xin Yi
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Yi, Xin, "Rnase L Manipulates Macrophages in Innate Immunity and Tumor Growth" (2012). ETD Archive. 316.
https://engagedscholarship.csuohio.edu/etdarchive/316
  
RNASE L MANIPULATES MACROPHAGES IN INNATE 
IMMUNITY AND TUMOR GROWTH 
 
 
XIN YI  
 
 
 
 
 Bachelor of Science in Biotechnology  
China Agricultural University  
     JUNE, 2007 
 
 
 
 
submitted in partial fulfillment of requirements for the degree 
DOCTOR OF PHILOSOPHY IN  
CLINICAL-BIOANALYTICAL CHEMISTRY 
at  
CLEVELAND STATE UNIVERSITY 
AUG, 2012
  
This dissertation has been approved 
for the Department of CHEMISTRY 
and the College of Graduate Studies by 
 
 
______________________________ 
Dissertation Chairperson, Dr. Aimin Zhou 
Department of CHEMISTRY  
 
____________________ 
Date  
 
 
______________________________ 
Dr. David Anderson 
Department of CHEMISTRY  
 
_________________________ 
Date  
 
 
______________________________ 
Dr. Michael Kalafatis 
Department of CHEMISTRY  
 
_________________________ 
Date  
 
 
______________________________ 
Dr. Wenquan Zou 
Department of Pathology and Neurology, Case Western Reserve University   
 
_________________________ 
Date  
 
 
______________________________ 
Dr. Xuelong Sun 
Department of CHEMISTRY  
 
_________________________ 
Date  
  
Acknowledgements 
 
First and foremost, I would like to express the deepest appreciation to my supervisor, Dr. 
Aimin Zhou, who has supported me throughout my research study with his patience and 
steadfast encouragement. He was always accessible and willing to help with my research, 
my English writing, and any problem I encountered in my life. His advice, kindness, as 
well as experience he shared with me in career and life have been invaluable to me.  I 
attribute my PhD degree to his guidance and effort. Without him, this thesis would not 
have been possible.  
I also would like to express my sincerest gratitude to my committee members. Dr. David 
Anderson, who introduced me to the clinical chemistry field, gave me unfailing support 
for my career progression and insightful advice.  Dr. Xuelong Sun, for his support with 
my work all the time and letting me use the facilities in his lab to help me successfully 
finish my project. Dr. Wenquan Zou, for his valuable comments and suggestion on my 
project and my annual report every year. Dr. Michael Kalafatis, for the insights and 
extremely helpful criticism he has provided.  
I am delighted to have collaborated with Dr. Bin Su and his group. His wide knowledge 
and his logical way of thinking have been of great value to me. His perpetual energy and 
enthusiasm in research have inspired and motivated me.  
  
I am indebted to my many colleagues for providing a stimulating and fun environment in 
which to learn and grow. I am especially grateful to Booseok Yun, Chun Zeng, Haiyan 
Tan, Lin Zhang, and our new group members, Qianyang Huang and Norah J Alghamdi.  
Most of the results described in this thesis would not have been obtained without a close 
collaboration with a few laboratories. I wish to extend my warmest thanks to all those 
who have assisted me and offered their support. Dr. Ge Jin and Dr. Sandra Siedlak in 
Case Western Reserve University for teaching me immunohistochemistry staining, and 
Dr. Xiaoxia Li and her lab members in Cleveland Clinic for teaching me to use the 
fluorescence microscope.  
I am particularly grateful to Dr. Michael Ip for mentoring me during my internship at 
Metro Hospital and for his continuous support and advice on my career goal to be a 
clinical laboratory professional.  
The financial support from the Doctoral Dissertation Research Expense Award Program 
is gratefully acknowledged.  
Last but not least, I would like to thank my family and friends. My entire family has been 
a constant source of support. Especially my dearest parents and Yibin, you all are my joy 
and my guiding light.  To you I dedicate this thesis.   
 
 
v 
 
RNASE L MANIPULATES MACROPHAGES IN INNATE 
IMMUNITY AND TUMOR GROWTH 
 
XIN YI 
 
ABSTRACT 
 
RNase L is one of the key enzymes in the 2-5A system of interferon (IFN) action against 
viral infection and cellular proliferation. Tissue distribution analysis has revealed that 
RNase L is highly expressed in the spleen, thymus, lung, testis, intestine and most of 
immune cells such as T, B cells and macrophages. However, the physiological role of 
RNase L in the immune system is largely unknown. My thesis thus focused on studying 
the possible physiological role of RNase L in macrophages.  
 
By using bone marrow-derived macrophages (BMMs) from RNase L+/+and -/- mice, we 
demonstrated that RNase L is involved in macrophage functions and migration ability.  
RNase L deficient BMMs showed a significant reduction of endocytic activity to FITC-
Dextran 40,000 compared to wild type cells. In addition, lack of RNase L remarkably 
decreased the migration of BMMs under both normal condition and condition induced by 
M-CSF, GM-CSF or CCL2. To determine the role of RNase L in tumor growth, P53-/- 
RL-/- cancer cells were subcutaneously implanted on the back of RNase L null and wild 
type mice with C57BL/6 background, respectively. Surprisingly, the average tumor 
weight from RNase L+/+ mice was 3-fold heavier than that from RNase L-/- mice 
vi 
 
indicating that presence of RNase L was overtly favorite for tumor growth. 
Immunofluorescence staining revealed that the numbers of infiltrated macrophages were 
markedly higher in the tumor tissues from the wild type mice. Depletion of macrophages 
clearly inhibited tumor growth on RNase L+/+ mice, suggesting that RNase L may 
promote tumor growth through regulating the function of tumor-associated macrophages 
(TAMs). Taken together, our findings implicate that RNase L may play a dual role in 
innate immunity and tumor promotion.  
 
Additionally, in a collaborated project, we successfully identified and investigated the 
molecular targets of an anti-cancer drug candidate. In this study, we performed protein 
pull down assays to purify the anti-cancer targets of the compound. Via proteomic 
approaches, the major proteins bound to the probe were identified to be tubulin and 
Hsp27, and the compound significantly inhibited tubulin polymerization and had the 
potential to be a class of new chemotherapeutic agents.  
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CHAPTER I 
INTRODUCTION  
 
 
1.1  2’-5’ oligoadenylate (2-5A) / RNase L system 
 
The 2’-5’ oligoadenylate (2-5A)/ RNase L system was first discovered in the mid-
1970s when researchers investigated how interferon (IFN) inhibits viral infection (1).  
Promising evidences showed that the 2-5A/RNase L system is an IFN-inducible RNA 
degradation pathway which is responsible for many of the antiviral and anti-proliferative 
effects of IFN. The 2-5A pathway comprises at least three important components, 2-5A 
synthetases (OAS), 2-5A degrading enzyme, and RNase L (Figure 1.1). The dsRNA 
generated from virus infection binds to and activates OAS. Once activatd, OAS converts 
ATP to PPi and a series of short 2’, 5’- linked oligoadenylates referred to as 2-5A 
molecules with the formula [ppp5’A(2’p5’A)n; , 2≤n] (Figure.1.1) (2). At subnanomolar 
levels, 2-5A binds with high affinity to RNase L and converts RNase L from its 
monomeric, an inactive form to a dimeric, active state, with endonucleolytic activity (3). 
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Activated RNase L could cleave single-stranded RNA (ssRNA) in U-rich sequences, 
typically after UU or UA dinucleotides leaving a 5’-OH and 3’-monophosphate (4, 5), 
leading to the degradation of viral RNA and also host cell mRNA, which  induces cell 
apoptosis (3,  6).  
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Figure 1. 1 Diagram of 2-5A/RNase L system. 
               (Chakrabarti A, Jha BK, Silverman RH. J Interferon Cytokine Res. 2011)
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1.2 Properties of RNase L  
 
RNase L is a highly regulated, latent endoribonuclease first cloned in 1993 (7). It 
is widely expressed in most mammalian tissues (8).  The cDNA of human RNase L gene 
encodes an 84 kDa protein with 741 amino acids. The structural and functional analysis 
of RNase L has revealed that this enzyme is composed of 3 major domains: an N-
terminal regulatory ankyrin repeat domain (ARD), a protein kinase (PK)-like domain, 
and a C-terminal ribonuclease domain (RNASE) (Figure 1.2). The N-terminal contains 9 
ankyrin repeats, which are one of the most common amino acid motifs, typically 
functioning in mediating protein–protein interactions(1, 2), suggesting that RNase L may 
interact with other proteins. RNase L has 8 complete ankyrin repeats and 1 partial repeat 
appearing as a disordered segment in the crystal structure of the N-terminal (amino acid 
1–333) of human RNase L (9). The unique feature of the ARD repeats in RNase L is that 
they interact with a nucleic acid, 2-5A. Repeats 2 and 4 in ARD are involved in 2-5A 
binding (Figure 1.2) (9). In its inactive state, the N terminal domain functions as a 
repressor of the ribonuclease domain in the C terminal domain (Figure 1.3). The 
minimum repressor function can be mediated by three ankyrin repeats, 7, 8, and 9 (10, 
11).  
 
The C-terminal part of RNase L has a cysteine rich region with a protein kinase 
homology although kinase activity of RNase L has not been demonstrated to date. The 
protein kinase-like and ribonuclease domains of RNase L [collectively referred to as the 
kinase-extentionuclease (KEN)] are homologous with Ire1, which is also a kinase and an 
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endoribonuclease that functions in the unfolded protein response (UPR) from yeast to 
humans (1, 11, 12). The KEN domain in RNase L functions in dimerization and catalysis. 
An isolated C-terminal domain of RNase L can cleave RNA in the absence of 2-5A (10, 
13). The RNASE domain becomes constitutively active upon removal of the ARD 
(although at 6-fold reduced activity compared with activated full-length protein) (10). 2-
5A binding to the N-terminal half probably induces a conformational change of the 
enzyme, causing the N-terminal repressor domain to release from the C terminal 
ribonuclease domain, and unmasks the dimerization domain (Figure 1.3).   
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Figure 1. 2 The structure of RNase L. 
               (Chakrabarti A, Jha BK, Silverman RH. J Interferon Cytokine Res. 2011) 
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Figure 1. 3 Functional model for the activation of RNase L by 2-5A. 
                           (Dong B, Niwa M, Walter P, Silverman RH. RNA. 2001) 
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1.3 Involvement of RNase L in the antiviral action 
 
RNase L is one of the key enzymes in the 2-5A system of IFN action against viral 
infection and cellular proliferation. The 2-5A system mediates host defense against 
certain types of viral infections. The most compelling evidence is the accumulation of 2-
5A and activated RNase L in virus-infected cells (14). Cells overexpressing RNase L 
overcome viral infection. In contrast, overexpression of a dominant negative mutant of 
RNase L results in increased susceptibility to viral infection, including picornaviruses, 
EMCV or Coxsackie virus B4, herpes simplex virus 1 (HSV-1), flavivirus, and West Nile 
virus (2, 15-18). In vivo studies show that mice containing targeted disruption of RNase 
L gene succumb to encephalomyocarditis (EMCV) infection more rapidly than infected 
wild type mice. Transfection of the 2-5A analog, CH3Sp(A2’p)2A2’pp3’OCH3, which 
binds to, but does not activate RNase L (19, 20) into IFN-treated, EMCV-infected murine 
L929 cells inhibited rRNA cleavage and increased virus production by up to 10 fold (21). 
Moreover, it is also notable that RNase L not only degrades RNA, but also regulates the 
expression of genes (22), which have antiviral function. It is believed that RNase L 
presents its antiviral effects through a combination of effect, including direct cleavage of 
viral RNA, inhibition of protein synthesis through the degradation of rRNA, induction of 
apoptosis, and induction of other antiviral gene expression (2). 
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1.4 Apoptotic activity of RNase L  
 
Several lines of studies have shown that activation of RNase L causes apoptosis.  
The 2-5A system is likely to contribute to the antiviral activity of IFN by inducing 
apoptosis of infected cells. Overexpression of dominant negative RNase L in cells 
reduced apoptosis whereas overexpression of wild-type RNase L enhanced the apoptosis 
in response to viral infection (21). However, evidences also shown that RNase L is 
involved in an apoptotic signaling pathway other than that induced by 2-5A. After down-
regulation of RNase L by siRNA in the prostate cancer cell line DU 145, cells were 
resistant to induced apoptosis (23). RNase L null mice showed enlarged thymus resulted 
from a suppression level of apoptosis and there was a 2-fold decrease in apoptosis in the 
thymuses and spleens of RNase L null mice. Furthermore, thymocytes and lymphocytes 
isolated from spleen of RNase L-null mice were resistant to apoptosis induced by 
apoptotic agents (15, 24). These results suggest that RNase L contributes to apoptosis. 
RNase L mediating apoptosis is through activation of a JNK-dependent stress response 
pathway, leading to cytochrome c release from mitochondria and subsequently activation 
of the caspase cascade.  Overexpression of Bcl-2 inhibits this process (25, 26). 
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1.5 The involvement of RNase L in cancer 
 
RNase L was initially proposed to be a candidate tumor suppressor based on its 
involvement in the antiproliferative activity of IFN and on the location of RNASEL at 
chromosome 1q25, a region deleted or rearranged in some breast cancers (2, 27-29). 
Studies have revealed that skin allograft rejection is suppressed in mice lacking RNase L, 
implicating the involvement of RNase L in T-cell immunity, particularly CD4+ T-cell 
mediated immunity (30). In addition, alphavirus-based DNA vaccination against a non-
mutated tumor-associate self-antigen (tyrosinase-related protein-1, TRP-1) is severely 
impaired in RNase L null mice, indicating that RNase L is involved in or required for 
host immune system against cancer (31).Moreover, RNase L was identified as a prostate 
cancer susceptibility gene by mapping hereditary prostate cancer 1 (HPC1) to the RNase 
L gene (2, 32). Recent studies in humans have demonstrated that mutations in RNASEL 
can enhance the risk of prostate cancer by about 50% (33-36). However, not consistent 
with other group’s results, my research study found that RNase L would promote rather 
than suppress tumor growth, through its modulation on macrophage functions and 
cytokine profile in tumor tissues.  
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CHAPTER II 
 
DEFECTIVE MACROPHAGE FUNCTIONS IN RNASE L 
DEFICIENCY 
 
 
2.1 Introduction of macrophage endocytosis and migration ability  
 
Macrophages are an essential part in innate immunity and adaptive immunity, as a 
frontline defense against invading disease or injury. Their roles include endocytosis to 
guard against microbial infections, migration to injury tissue, and production of an 
assortment of cytokines, which could regulate tissue remodeling and local tissue 
inflammatory response (1, 2).  
 
2.1.1 Introduction of Macrophages  
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2.1.1.1 Macrophage generation  
Blood monocytes are known to arise in the bone marrow from precursor cells 
(monoblasts) that are derived from the differentiation of multipotential progenitors.  
Blood monocytes are then released into the peripheral blood, and circulate for several 
days before entering into inflamed or infected tissues, where they can mature into 
macrophages and substantially augment resident macrophage populations throughout the 
body, as well as give rise to specialized cells as dendritic cells (DCs) and osteoclasts.  
Dendritic cells could efficiently present antigen to T cells and osteoclasts are the cells 
that resorb, or break down and absorb, bone tissue back into the body (Figure 2.1) (3, 4, 
5). 
 
2.1.1.2 Macrophage heterogeneity 
 
 
In the absence of inflammation, monocytes are found principally in the marrow 
and blood. In 1939, Ebert and Florey firstly reported the observation that monocytes 
emigrated from blood vessels and developed into macrophages in the tissues, where they 
differentiate into typical tissue macrophages and assume different morphologic and 
functional properties depending on their location and environment in organs and tissues 
(4, 6-8). In the adult, large populations of tissue macrophages exist in the small intestine, 
liver (Kupffer cells), and lungs (alveolar and interstitial macrophages), but they are also 
found in the spleen, lymph nodes, bone marrow, peritoneal and pleural serosal cavities, 
kidneys and endocrine glands, and  brain (microglia) (3). Studies of the mononuclear-
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phagocyte system, using monoclonal antibodies specific for various cell-surface receptors 
and differentiation antigens, have shown that there is substantial heterogeneity of 
phenotype, which most probably reflects the specialization of individual macrophage 
populations within their microenvironments and result in different physiological roles of 
the subsets in vivo. However, the determinants of this tissue-specific differentiation 
remain unrevealed (4).   
             
                                                   
 
Figure 2. 1 Development and function of monocyte subsets. 
              (Siamon Gordon, Philip R. Taylor. Nature Reviews Immunology. 2005) 
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2.1.1.3 Macrophage functions and its relevance in diseases  
 
 
Macrophages play a central role in the immune system through presenting 
antigens to directly activate T-lymphocytes, participating in ingestion and killing of 
various invading or infectious microorganisms (9). In addition, macrophages have cell 
surface receptors for a variety of substances (e.g., IgG, complement components, 
fibronectin, and sugars) and are capable of secreting a great number of mediators 
involved in host defense and inflammation response (10, 11, 12). Tissue specific 
macrophages also express specific functions in particular anatomic sites and organs. 
During infection, macrophages have the capacity to become activated by both specific 
and nonspecific immunologic stimuli such as lymphocyte cytokines and different 
bacterial products, and the activated macrophage has enhanced functional capabilities in 
inflammatory responses, antigen presentation, and immunoregulatory networks (10).  
Because of the central role in host defense, abnormal monocyte/macrophage function 
may result in pathophysiologic consequences and have been described in various 
disorders such as deficiencies in the clearance of physiologic substrates in lysosomal 
diseases, decreased secretion of mediators (complement component deficiencies), 
deficiencies in the clearance of physiologic substrates in lysosomal diseases, defects in 
microbicidal activity (chronic granulomatous disease) and defects which are acquired 
following infection and during chemotherapy (e.g., HIV) (10,12, 13).  
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2.1.2 Macrophage endocytosis and phagocytosis  
 
Macrophages are cells that function in both innate and adaptive immunity and can 
exert protective and pathogenic activity through ingesting specific matter efficiently by 
phagocytosis and endocytosis. These processes are essential for the removal of pathogens 
and macrophage antigen presentation (14, 15). During endocytosis, the plasma membrane 
of the cell forms a pocket (endosome or phagosome) around the material to be 
internalized including fluid, large and small molecules, and even other cells from their 
surroundings. Endocytosis includes the processes of phagocytosis, receptor-mediated 
endocytosis, and fluid phase endocytosis/pinocytosis, contributing to multiple pathways 
of cell homeostasis, development of immune responses to soluble antigens, and infection 
by intracellular pathogens (Figure 2.2) (16).  
 
2.1.2.1 Pinocytosis and Receptor-mediated endocytosis  
 
Pinocytosis usually refers to the uptake of fluid and solutes, which brings fluid 
and material into the cell and removes membrane from the plasma membrane with a 
continuous stream of vesicles budding. Receptor-mediated endocytosis selectively 
internalizes specific molecules that are bound to receptors on the outside surface of the 
cell, such as hormones, growth factors, antibodies, iron, enzymes, vitamins, and 
cholesterol. Once molecules bind to their receptors, the receptors move within the plasma 
membrane and the inside surface of the plasma membrane then progressively invaginate, 
or form inward,  form a membrane-enclosed bubble, or vesicle, containing the ingested 
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material. The basketlike structure vesicles pinch off the plasma membrane into 
the cytoplasm and fuses with another membranous organelle called endosome (17, 18).   
In 1985, Brown and Goldstein won the Nobel Prize in medicine for their discovery of the 
endocytosis of cholesterol and lipoprotein (LDL) by cells from the bloodstream (19). 
Moreover, endocytosis is an important step in presenting antigens to generate acquired 
immunity and more recently, studies also found that endocytosis can be utilized by 
viruses to enter cells (20-22).   
    
2.1.2.2 Phagocytosis  
 
Phagocytosis is also important in processing and presenting antigens to T cells, 
and moreover, it could defend the body against infection by engulfing invading 
microorganisms and to remove cell debris from the body by ingesting damaged or old 
cells. In phagocytosis, cell membrane extend and project large vesicles surrounding the 
particle and fuse together so that the particle is completely engulfed in large vesicles 
within the cell, which are called phagosome (24). Inside the cell, the phagosome fuses 
with another membranous organelle called lysosome, forming a single membranous 
organelle and mixing their contents and breaking down the ingested materials into small 
molecules in the process (3). In phagocytosis and receptor mediated endocytosis, 
macrophages have evolved a restricted number of receptors, like the mannose receptor, 
that recognize conserved motifs on pathogens (25).  
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However, in phagocytosis and receptor-mediated endocytosis, different receptors 
and underlying molecular mechanisms are utilized for internalizing different agents (25). 
These differences include the cytoskeletal elements that mediate ingestion, vacuole 
maturation, and inﬂammatory responses (25, 26). Infectious agents, such as M. 
tuberculosis, Legionella pneumophila, and Salmonella typhimurium, enter macrophages 
via heterogeneous pathways and modify vacuolar maturation in a manner that favors their 
survival (26).            
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Figure 2. 2 Endocytosis includes the processes of phagocytosis, receptor-mediated 
endocytosis, and fluid phase endocytosis/pinocytosis. 
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2.1.3 Macrophage migration 
 
When monocytes enter damaged tissue through the endothelium of a blood vessel, 
it undergoes a series of changes to become tissue specific macrophages. Monocytes are 
attracted to a damaged site by chemical substances through chemotaxis, triggered by a 
range of stimuli including damaged cells, pathogens and cytokines released by 
macrophages already at the site. The recruitment of macrophages to an inflammatory site 
is a complex process involving their adhesion to endothelial cells, passage into the 
perivascular connective tissue, and migration toward a chemotactic gradient (27, 28). 
Chemokine C-C motif ligand (CCL) 2, also known as monocyte chemoattractant protein 
1 (MCP-1) is a member of the cytokine/chemokine superfamily and is revealed to 
promote the migration of monocytes and macrophages to sites of inflammation (29-32), 
as mice deficient in CCL2 have decreased recruitment of macrophages in response to 
infection (33).  Furthermore, macrophages from CCL2 deficient mice with impaired 
migration activity also produced lower amounts of IL-10 and tumor necrosis factor 
compared with wild-type mice (34). In addition to being a cytokine synthesis-inhibitory 
factor, IL-10 was also reported to facilitate macrophage migration through its inhibitory 
effect on macrophage migration inhibitory factor (MIF) (35). Moreover, TGF-β and M-
CSF are also important factors known to attract macrophage recruitment into 
inflammation sites and tumor tissues (36, 37). Macrophages, in particular, secret TGF-β, 
which in turn stimulates the migration of macrophages. It was reported that TGF-β 
induced mRNA and protein level of CCL2 in macrophages, and this induction was 
mediated by RhoA (36). 
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2.1.4 Highly expressed RNase L in macrophages 
 
RNase L is present at basal levels in most mammalian cells. Tissue distribution 
analysis has revealed that RNase L is highly expressed in the spleen, thymus, lung, testis, 
intestine and most of immune cells such as T, B cells and macrophages. However, the 
physiological role of RNase L in the immune system, especially in macrophages, is 
largely unknown. In the present study, we demonstrated that RNase L contributes to 
macrophage endocytosis and migration ability by using BMMs from RNase L wild type 
and knocked out mice. Furthermore, significantly higher expression of CCL2, TGF-β, IL-
10 and COX-2 was observed in cells in the presence of RNase L, suggesting that RNase 
L may regulate the expression of cytokines and chemokines in macrophages to modulate 
their immune functions. Taken together, our findings provide new insight into how 
RNase L regulates macrophage function, and suggest a novel role of RNase L in 
macrophage-dependent immune response.    
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2.2 Materials and Methods 
 
2.2.1 Culture and activation of macrophages from mouse bone marrow  
 
Bone marrow-derived macrophages (BMMs) were generated from the bone 
marrow of RNase L wild type and deficient C57BL/6 mice by a modification of a 
previously reported method. Bone marrow cells were isolated from femurs by repeated 
flushing of the bone shaft with cold medium and cultured in RPMI 1640 medium 
(Cleveland Clinic, OH) supplemented with 10ng/ml recombinant murine macrophage-
colony stimulating factor (M-CSF, Shenandoah Biotechnology, PA), 20% fetal bovine 
serum (FBS), and 10% L292-conditioned medium (LCM) which contains abundant M-
CSF. RPMI medium stands for Roswell Park Memorial Institute medium, and it is 
traditionally used for the cultivation of many cell types, especially human T/B-
lymphocytes, bone marrow cells and hybridoma cells. Macrophage colony-stimulating 
factor (M-CSF) is a secreted cytokine essential for both the proliferation 
and differentiation of monocytes/macrophages from hematopoietic stem cells. 
Macrophages generated from mouse bone marrow cell culture were harvested after 7days 
culture and were used for in vitro experiments. To assess macrophage endocytosis, 
phagocytosis ability and cell motility, macrophages were activated with LPS (0.5μg/ml) 
for 48 hours.  
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2.2.2 Endocytosis and phagocytosis assay 
 
As introduced in 2.1.2, macrophages internalize specifically-targeted particular 
ligands through receptor-mediated endocytosis and phagocytosis, whereas pinocytosis is 
a less specific mechanism of endocytosis. To assess whether RNase L influences 
macrophage most important functions, specific ligands conjugated with fluorescence 
signal were selected to assess macrophage endocytosis and phagocytosis ability. As 
shown in Table 2.1, FITC-Dextran 40,000 (Sigma, MO) was used to determine 
macrophage endocytosis and FITC-conjugated E. coli particles (Molecular Probes, 
Invitrogen, CA) were selected to study macrophage phagocytosis. Cells were washed 
twice with cold PBS, and incubated in fresh DMEM (10% FBS, 25mM Hepes) with 
FITC-Dextran 40,000 (1g/ml) or FITC-E.coli (bacterial to macrophage ratio=50:1) at 
37℃ for 1 hour. Control groups were incubated on ice. After incubation, cells were fixed 
with 4% paraformalhyde for 10 min and fluorescence of extracellular particles was 
quenched with 1-2 ml 0.02% trypan blue for 3 minutes.  Prolong cold antifade reagents 
with 4', 6-diamidino-2-phenylindole (DAPI) (Invitrogen, CA) were used as mounting 
solution. DAPI binds strongly to A-T rich regions in DNA and is wildly used in 
fluorescence microscopy to stain cell nucleus.  Prepared slides were allowed to dry and 
observed under microscope.  
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Probe  Supplier  Receptor  
Texas red dextran (40,000 or 
70, 000 MW)  
Molecular Probes  Unknown  
FITC holo-transferrin  Molecular probes  Transferrin receptor  
Di-I LDL  Per lmmune  LDL receptor  
Di-I acetylated LDL  Per lmmune  SR-A,CD36,MARCO  
HRP  Sigma  Mannose receptor 
on macrophages  
Lucifer yellow  Sigma  Fluid phase  
Mannosylated BSA  E-Y lab  Mannose receptor  
Latex bead  Sigma  Unknown  
Sheep erythrocytes  Diamedix, Miami, 
FL  
CR3 if coated with 
complement FcR if 
coated with IgG  
FITC-E.coli bioparticles  Molecular Probes  Multiple  
FITC-S.aureus bioparticles  Molecular Probes  Multiple  
Zymosan  Sigma  MR and b-glucan 
receptor  
Table I. Commonly used endocytic tracers and phagocytic particles in experiment. 
                         (Book: Macrophages. Donna M. Paulnock. 2000 Oct; page 83) 
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2.2.3 Macrophage in vitro migration assay 
 
For studying macrophage migration ability, BMMs were used to perform in vitro 
transwell cell migration assay (Figure 2.3).  The transwell migration assay is performed 
by adding cells to the upper, coated surface of the transwell inserts and medium with 
chemoattractant to the lower well of the chamber. After incubation, especially under the 
induction of chemoattractant, cells invade through the matrix barrier and pass through the 
pores on the membrane, and migrate onto the lower surface of the inserts and attach on it. 
Migrated cells can be quantified by methods as simple as fix/stain and count.  
 
When BMMs grew to 80% confluence, growth medium was replaced with serum 
free DMEM to starve cells for 20 hours. Transwell filter inserts (8μm pore size; Greiner 
bio-one) were coated with 20μg/ml fibronetin (from human plasma; Sigma, MO), which 
helps the attachment of migrated cells on the membrane, at 4°C overnight. After 
aspirating solution out of apical and lower chamber, macrophages (2.07x105) were 
seeded in the upper chamber with serum free DMEM. In the lower chamber, media with 
different macrophage migration stimulator were added respectively, including serum-free 
DMEM, DMEM, DMEM with M-CSF (100ng/ml), or with IFN-γ (100 μg/ml), or with 
GM-CSF (100ng/ml). Cells were incubated at 37°C for overnight to allow enough time to 
migrate. After incubation, chambers were turned upside-down and gently submerged in 
PBS several times to remove unattached cells. Then cells left on membrane were firstly 
fixed with 10% formalin, and then stained with eosin for 5 minutes. Under the 
microscope, cells were counted in x200 fields and averaged.  
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Figure 2. 3 Illustration for tranwell insert cell migration assay. 
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2.2.4 Cytokine enzyme-linked immunosorbent assay (ELISA) 
 
 
ELISA is a widely used method for measuring the concentration of a particular 
molecule in a fluid such as serum, urine or cell culture medium. It is performed in a 96-
well plate with a high throughput result and high sensitivity.  
 
To determine certain cytokine and chemokine secretion level in macrophages, 
ELISA was performed with macrophage cell culture medium. Primary macrophage and 
RAW 264.7 macrophage cell culture medium were collected and CCL2, TGF-β, M-CSF 
and IL-10 secretion was measured with commercially available ELISA kits (eBioscience, 
CA).  The ELISA process is shown as in Figure 2.4. Briefly, according to manufacturer’s 
directions, flat bottom 96 well ELISA plates were coated with a capture antibody at 4°C. 
After overnight incubation at 4°C, the plates were washed three times, blocked with 
blocking buffer provided in the kit and then incubated with standards or cell culture 
supernatant samples for 2 hours at room temperature. Serial dilutions of standard 
solutions were run in duplicate on each plate. After washing the plates, biotinylated 
detection antibody was added to each well and incubated for 1 hour, which followed by 
washing and 30 minutes incubation of strepavidin peroxidase.  Substrate containing 3, 3' 
5, 5'-tetramethylbenzidine (TMB) and hydrogen peroxide was added into plates, and 
phosphoric acid was used as stop solution after 30 minutes.  Plates were read at 450nm 
within an automated microplate reader and cytokine concentrations were determined 
against the standard curve.   
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Figure 2. 4 Main steps of the Sandwich ELISA Kit. 
    
                   (http://www.epitomics.com/products/product_info.  Epitomics, Inc.) 
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2.2.5 RNase L knocked down in RAW264.7 macrophage cell line 
 
2.2.5.1 RNA interference (RNAi) and short hairpin RNA (ShRNA) lentiviral 
particles  
 
RNA interference (RNAi) was first identified in 1997 in C. elegans by Fire and 
Mello as a biological response to exogenous double-stranded RNA (dsRNA), which 
induces sequence-specific gene silencing (38). It is a natural process that expression of a 
targeted gene can be knocked down with high speciﬁcity and selectivity (39). The 
discovery introduced an extraordinarily powerful and promising laboratory tool for 
researchers, and also has exciting clinical potential. The RNAi pathway is initiated by the 
enzyme Dicer, which cleaves long dsRNA molecules into short fragments of ~20 
nucleotides that are called small interfering RNA (siRNA). SiRNA assembles with 
the RNA-induced silencing complex (RISC) and unwound into two single-stranded (ss) 
RNAs. One of the two strands will be degraded, and the guide strand remaining on RISC 
specifically binds with a complementary sequence of mRNA and induces cleavage by the 
catalytic component of the RISC complex, resulting in post-transcriptional gene silencing 
(40) (Figure 2.5).  
 
Methods of mediating the RNAi effect involve siRNA and short hairpin RNA 
(shRNA), which is packed and transfected as shRNA plasmid or shRNA lentiviral 
particles (Figure 2.6) (39). siRNA provides a fast and efficient, though short-term, 
decrease in target gene expression, whereas shRNA plasmids or shRNA lentiviral 
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particles transfection is more stable and last longer. A transfection reagent is required 
when siRNA and shRNA plasmid are used. With the same encoded sequence against a 
target gene, shRNA lentiviral particles are ready to tranduce by directly adding them to 
cell culture. Moreover, shRNA lentiviral particles can easily transduce typically hard-to-
transfected cell lines, such as primary cells, non-dividing cells, and also macrophages.   
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Figure 2. 5 RNAi machinery.                                                 
                         (Daniel C, Doris L, Volker WK. Clinical Science. 2006) 
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Figure 2. 6 siRNA, shRNA Plasmid and shRNA Lentiviral Particles as gene silencer. 
               (http://www.scbt.com/gene_silencers.html Santa Cruz Biotechnology, CA) 
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2.2.5.2 RNase L knocked down in RAW264.7 cell line 
 
RAW264.7 cells were cultured in a 12-well plate to 50% confluent on the day of 
infection. Fresh complete medium with Polybrene (Santa Cruz Biotechnology, CA) at a 
final concentration of 5μg/ml was added in each well and cells were infected by directly 
adding mouse RNase L shRNA lentiviral particles or control shRNA lentiviral particles 
in the control group. After overnight incubation, culture medium was replaced with 
complete medium without Polybrene or shRNA lentiviral particles. RNase L and Control 
shRNA lentiviral particles contain a puromycin resistant gene, which enables stably 
tranduced cells to survive in puromycin selective culture medium. Puromiycin 
dihydrochloride (10mg/ml) was added after 2 days to select shRNA stably transduced cell 
colonies. A puromycin titration over RAW264.7 cells was performed previously to select 
an amount sufficient to kill the non-transduced cells. Medium with fresh puromycin was 
replaced every 3-4 days in two weeks, until resistant colonies can be formed. All stably 
transuded colonies were picked and expanded to check the expression level of RNase L 
by Western Blot.  
 
2.2.6 Determination of  RNase L protein expression level with Western Blot  
 
2.2.6.1 Introduction of western blot  
 
Western blot is a widely used technique for detection of known proteins in the 
given sample of tissue homogenate or extract with specific antibodies. It comprises four 
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parts, including protein separation by gel electrophoresis, protein transference, antibody 
blotting, and probe detection. The most common type of gel electrophoresis is SDS 
polyacrylamide gel electrophoresis (in x200 fields), which employs polyacrylamide gels 
and loaded with sodium dodecyl sulfate (SDS) buffer.  Polypeptides were denatured by 
treating with strong reducing agents to remove secondary and tertiary structure and thus 
allow SDS-PAGE to separate proteins only by their molecular weight. When voltage is 
applied along the gel, proteins migrate into it at different speeds. Smaller proteins migrate 
faster through the gel and therefore proteins in samples can be separated by their different 
molecular weight (Figure 2.7).  
 
After gel electrophoresis, proteins are transferred from the gel to a membrane 
such as polyvinylidene difluoride (PVDF) or nitrocellulose membrane, by wet (tank) 
transfer or semi-dry transfer. An antibody is then added onto the membrane which is able 
to bind to its specific protein. After washing, a secondary antibody conjugated with an 
enzyme (e.g. alkaline phosphatase or horseradish peroxidase) will be used, which could 
be detected by incubating it with a substrate, usually chemiluminescent substrate. The 
attached enzyme could convert colorless substrate to a colored product that can be 
detected and photographed (Figure 2.8).  
 
 
 
39 
 
 
 
 
 
            
Figure 2. 7 Separation of proteins in SDS-PAGE according to molecular weight. 
         (http://www.imb-jena.de/~rake/Bioinformatics_WEB/proteins_purification.html) 
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Figure 2. 8 Detection of horseradish peroxides (HRP)-linked secondary antibody. 
                    (http://www.cellsignal.com/products/7072.html, Cell Signaling, CA) 
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2.2.6.2 Determine RNase L expression level by Western Blot.  
 
All western blot experiments performed here were using SDS-PAGE and wet 
(tank) transfer. Cells were lysated in RIPA lysis buffer (5ml 1M tris HCl pH 7.4, 3ml 5M 
NaCl, 1ml 10% NP40, 0.5g sodium deoxycholate, 1ml 0.5M EDTA 0.2ml 0.5M EGTA, 
0.1% SDS ) with freshly added a protease inhibitor cocktail (Calbiochem, CA), and 
followed by centrifugation. Protein samples were separated on 10% SDS-PAGE gel and 
thereafter transferred onto PVDF membrane (Pall Cooperation, FL). After blocking, the 
membrane was incubated in PBST containing 5% non-fat milk and a polyclone antibody 
specific to RNase L (1:1000 dilution, generated in our lab) over night at 4°C.  HRP-
conjugated anti-rabbit IgG (1:2000 dilution, Cell Signaling, MA) was used as a secondary 
antibody and incubated at room temperature for 1hour. The membrane was incubated in 
an ECL plus reagent (GE health, OH) and then exposed to hyper film.  
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2.3 Results 
 
2.3.1 RNase L enhances the extent of macrophage endocytosis 
 
Endocytosis plays an essential role in cell physiology and pathology. The 
pathways followed by particles internalized by its three main models (fluid-phase 
endocytosis, receptor-mediated endocytosis and phagocytosis) have been amply 
delineated in innate and adaptive immunity. We found from our previous studies that 
RNase L was highly expressed in macrophages. To determine if RNase L influences 
macrophage endocytosis activity, endocytosis and phagocytosis assay was performed. In 
endocytosis assay, bone marrow-derived macrophages (BMMs) from RNase L deficient 
and wild type mice were incubated with FITC-labeled Dextran 40,000 after activation by 
lipopolysaccharine (LPS) and fluorescence of engulfed FITC-Dextran 40,000 was 
observed and analyzed under a microscope. As shown in Figure 2.9A, FITC-Dextran 
40,000 were internalized at a higher level in macrophages from RNase L+/+ mice, 
compared to the cells in the absence of RNase L. Average numbers of total cells and cells 
ingested FITC-Dextran 40,000 or FITC-E.coli was counted from 8 fields under a 
microscope. In the endocytosis assay, 61.1±5.0% of RNase L+/+ macrophages was 
observed with endocytosis, but only 34.0±8.3% RNase L-/- macrophages accounted for 
total cells (Figure 2.9B).  The lack of RNase L in macrophages resulted in a dramatic 
reduction of endocytosis ability by 30%. However, when activated macrophages were 
exposed to FITC-labeled E. coli, similar amount of E.coli were efficiently phagocytosed 
by RNase L+/+ and RNase L−/− macrophages (Figure 2.10A). As shown in Figure 
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2.10B, 67.4 ± 5.4% of RNase L+/+ and 64.5 ± 3.0% of RNase L-/- macrophages 
internalized FITC-E.coli in phagocytosis assay, indicating that phagocytosis activity of 
E.coli by macrophages was not altered in the deficiency of RNase L. Experiments were 
repeated 3 times and  similar results were obtained. 
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Figure 2. 9 RNase L enhances endocytosis of FITC-DX40, 000 in macrophages. 
(A) Deficient endocytic capacity of FITC-Dextran 40000 was observed in BMMs in the 
absence of RNase L. (B) Average numbers of total cells and cells ingested FITC-Dextran 
40,000 was counted from 8 fields under a microscope. In the endocytosis assay, 
61.1±5.0% of RL+/+ and 34.0±8.3% of RL-/- macrophages was observed with endocytosis. 
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Figure 2. 10 RNase L does not affect macrophage phagocytosis of FITC-E.coli. 
(A) RL+/+ and RL-/- macrophages have efficient and similar phagocytic ability to engulf 
FITC-E.coli. (B) Average numbers of total cells and cells ingested FITC-E.coli was 
counted from 5 fields under a microscope. In the phagocytosis assay, 67.4±5.4% of RL+/+ 
and 64.5±3.0% RL-/- macrophages internalized FITC-E.coli. 
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2.3.2 RNase L deficiency represses migration ability of BMMs 
 
We next studied the influence of RNase L on macrophage migration by using in 
vitro transwell cell migration assay. BMMs were seeded on transwell filter inserts with 
pore size at 8um. M-CSF, GM-CSF and CCL2 were added respectively to trigger 
macrophage migration. Migrated cells were stained (red dots) with eosin.  
 
As shown in Figure 2.11A, fresh serum, M-CSF, GM-CSF, and CCL2 all 
successfully triggered macrophage migration in vitro. Moreover, not only after treatment 
of M-CSF, GM-CSF, and CCL2, but also in normal condition (Serum free and Serum 
group),  RNase L deﬁciency resulted in signiﬁcantly reduced  migration of macrophages 
when compared with wild type control, and the  difference in the migration level between 
RNase L +/+ and RNase L -/- macrophages was more clear with statistic analysis (Figure 
2.11B). This result indicated the involvement of RNase L in macrophage migration. 
Furthermore, RNase L was capable to modulate macrophage migration without any 
inducement, suggesting that the regulation of RNase L on macrophage migration was 
independent of M-CSF, GM-CSF, and CCL2 inducement, and RNase L plays a central 
role in macrophage migration.  
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Figure 2. 11 RNase L deficiency represses migration ability of BMMs. 
(A) Eosin staining and (B) migrated cell number counting showed that, not only after 
treatment of M-CSF, GM-CSF, and CCL2, but also in normal condition (Serum free and 
Serum group),  RNase L deﬁciency resulted in signiﬁcantly reduced migration of 
macrophages when compared with wild type control, 
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2.3.3 Effect of RNase L on macrophage cytokine production  
 
Macrophages are known to secret a large number of cytokines and chemokines, 
which in turn to regulate the characteristics of macrophages (22). Since RNase L has 
strong capability to modulate macrophage migration, we were intrigued to study the 
effect of RNase L on macrophage migration inducing factors. In our study, the secretion 
of CCL2, TGF-β, M-CSF and IL-10, which were found to be positively associated with 
macrophage migration, were determined in RNase L +/+ and -/- macrophage cell culture 
medium by using ELISA. Our data showed that secretion of CCL2 was greatly reduced 
without RNase L after induction by LPS or M-CSF, whereas the reduction was not 
clearly detectable without treatment (Figure 2.12A). Similar results were obtained for 
TGF-β and IL-10 (Figure 2.12B, D).  However, the M-CSF secretion level was not 
reduced in the deficiency of RNase L, and in contrast, a larger amount of M-CSF was 
detected in RNase L -/- macrophage cell culture medium after LPS treated (Figure 2.12C).  
 
To extend this finding from primary macrophage cells to mouse macrophage cell 
line RAW264.7, we constructed a RAW 264.7 cell line in which RNase L was 
constitutively knocked-down by shRNA lentiviral particles. Lentiviral particles are 
provided as transduction-ready viruses, delivering a shRNA encoding plasmid to target 
cells for stable knock-down of a target gene. Cell colonies stably transduced with shRNA 
Lentiviral particles were selected by puromycin for two weeks. The RNase L protein 
level was then determined in selected colonies and as shown in Figure 2.13A, RNase L 
was clearly knocked down in the RAW106 cell line in comparison to RAW Con which 
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was transfected with shRNA control lentiviral particles.  To confirm the effect of RNase 
L on macrophage migration related factors, we performed an ELISA assay to determine 
the secretion level of CCL2, TGF-β, M-CSF and IL-10 in RAW Con and RAW106 cells. 
As shown in Figure 2.13B, similar to what we observed in BMMs, a reduction level of 
CCL2, TGF-β and IL-10 was found in RAW106 cells compared to RAW Con cells, only 
treated with LPS or M-CSF. In contrast to other migration inducing factors, the level of 
M-CSF was elevated in RNase L knocked-down macrophages compared to RAW Con 
cells. Nevertheless, our results demonstrated that RNase L positively regulates the 
secretion of CCL2, TGF-β, and IL-10 in macrophages. With the reduction of those 
migration related factor, deficiency of RNase L may consequently resulted in declined 
migration ability of macrophages.    
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Figure 2. 12 Effect of RNase L on BMMs cytokine and chemokine production. 
Secretion of CCL2 (A), TGF-β (Β) and IL-10 (D) was greatly reduced in RNase L 
deficient BMMs after induction of LPS or M-CSF, whereas the reduction was not clearly 
detectable without treatment. (C) M-CSF secretion level was not reduced, but elevated in 
the deficiency of RNase L after LPS treatment. 
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Figure 2. 13 Effect of RNase L on migration inducing factors in RAW264.7 cells.  
(A) In RAW106 cells, RNase L was successfully knocked down compared to RAW Con 
cells. (B) Similar results of the secretion of migration inducing factors were obtained in 
RAW106 and RAW Con as in BMMs.   
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2.4 Discussion  
 
 
This study is the first time to demonstrate that RNase L is associated with 
macrophage functions, including endocytosis, migration, and cytokine production, which 
all have crucial significances for the innate immune system. Although other groups have 
reported that RNase L plays an important role in innate immunity through antiviral 
immune response (41), the involvement of RNase L in macrophage functions has never 
been determined.  
 
In phagocytosis and receptor mediated endocytosis, macrophages have evolved a 
restricted number of receptors, like the mannose receptor, that recognize conserved 
motifs on pathogens. However, in phagocytosis and receptor-mediated endocytosis, 
different receptors and underlying molecular mechanisms were utilized for internalizing 
different agents. FITC-Dextran is mainly taken up through the mannose receptor into 
macrophages (42, 43), and the entry of FITC-E.coli requires Fc receptor and scavenger 
receptors (44, 45). Our results suggested that RNase L may stimulate mannose receptor-
mediated endocytosis. Transient transfection with the mannose receptor cDNA revealed 
that mannose receptors were sufficient to mediate phagocytosis of Candida albicans, 
zymosan, Pneumocystis carinii, Klebsiella, and mycobacteria, as well as endocytosis of 
radiolabeled mannose-BSA glycol conjugate, indicating that the mannose receptor is both 
a major phagocytic and an endocytic receptor and is able to engage pathogens directly 
(46-48). Therefore, no alternation on phagocytosis of FITC-E.coli does not rule out the 
possibility that RNase L may also influence on macrophage phagocytosis, especially a 
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process to enter cells via mannose receptor. Ongoing work is focused on elucidating the 
molecular mechanism underlying the regulation of RNase L on mannose receptor-
mediated endocytosis.    
 
Macrophage migration is regulated by cytokine profile it produced. In a complete 
cell culture medium, deficiency of RNase L resulted in decreased macrophage migration 
activity, whereas a strong alternation was only observed in TGF-β expression, but not 
CCL2, IL-10, or M-CSF.  This experiment suggested it is with high possibility that TGF-
β, rather than CCL2, IL-10, and M-CSF, is involved in the direct regulation of RNase L 
on macrophage migration. In addition, RNase L played an important role in the induction 
of CCL2, TGF-β, and IL-10 by both LPS and M-CSF, and with the positive correlation 
between those factors and macrophage migration, RNase L may indirectly stimulate 
macrophage migration. Although those speculations were not confirmed here, further 
studies will provide insights into this hypothesis.   
 
In summary, we provide the data to indicate that RNase L is not only required for 
efficient macrophage endocytosis, but also migration ability. We further report that 
RNase L has the capability to regulate macrophage cytokine profile, which may be 
involved in regulating macrophage migration ability. Taken together, our findings 
provide new insight into how RNase L regulates macrophage functions, and suggest a 
novel role of RNase L in immunity.   
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CHAPTER III 
 
 
RNASE L MANIPULATES TUMOR-ASSOCIATED  
MACROPHAGES (TAMs) IN TUMOR GROWTH 
 
 
3.1 Introduction of tumor-associated macrophages (TAMs) 
 
3.1.1 Macrophage polarization  
 
Macrophages display significant heterogeneity in function, with remarkable 
plasticity and can change their physiology in response to local environmental factors (1, 
2). Different environmental stimuli activate macrophages to express distinct chemokines, 
cytokines and surface markers, and ultimately give rise to various subsets of 
macrophages with diverse functions in inflammatory and noninflammatory settings (2, 3). 
According to their ability to regulate inflammatory response, macrophage activation has 
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been operationally classified into 2 major polarization states.  Type 1macropahges (M1) 
are generally characterized by elevated expression of inflammatory cytokines, including 
interleukin (IL-12), tumor necrosis factor α (TNF-α), reactive oxygen species and nitric 
oxide (NO). M1 type macrophages are induced by endo- and exogenous stimuli, such as 
IFN-γ and LPS, and are involved in Th1 type response and engaged of Toll-like receptors 
(TLRs) (4). Type 2 macrophages (M2), also known as alternative activated macrophages, 
are diverse, but in general, are induced by IL-4, IL-13, IL-10 and TGF-β (3, 5) and 
involved in Th-2 type response, including humoral immunity and wound healing (4, 5).  
Also, M2 macrophages have low pro-inflammatory cytokine expression and are believed 
to participate in the blockade of inflammatory responses and in the promotion of tissue 
repair and tumor progress (3, 6-8). Systematic analysis of M1 and M2 macrophages 
revealed that a distinct stimulus is able to induce a specific macrophage phenotype with 
unique functional properties (Figure 3.1).   
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Figure 3. 1 The orchestration of macrophage activation and polarization.    
(BioLegend)             
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3.1.2 Dual role of macrophages in tumor growth   
 
 
As previous described, monocytes are recruited from the circulation into 
surrounding tissues, either normal healthy tissues or sites of injury, inflammation, 
malignancy where they differentiate into tissue macrophages. Macrophages, as well as 
dendritic and natural killer cells, are attracted into tumor tissues.  
 
The local microenvironment is critical for macrophage differentiation and 
activation. Investigators have found that macrophages infiltrated into tumor tissues have a 
dual role on tumor progression through either helping or inhibiting tumor cell growth (4, 
9). In tumors, macrophages activated by microbial products or interferon γ (IFN-γ) to 
express an M1 phenotype and express high levels of proinflammatory cytokines and 
major histocompatibility complex. The classical phenotype of macrophages (M1) in 
tumors participate in the immune response against tumor progressions by directly 
presenting tumor antigens to activate T cells  and rapidly secreting cytokines to attract 
more dendritic and NK cells, which could stimulate the cytotoxic lymphatic system 
against tumor growth. Additionally, in situ evidence proved that macrophage 
phagocytosis is also a critical mediator of tumor immune surveilance to phagocytose 
tumor cells (10).   
 
However, recent work has shown that tumor cells, besides having the capability to 
acquire stem-cell like machinery to allow self-renewal, are also able to escape the 
immune system when tumor immunosurveillance is not sufficient (11). Once tumor cells 
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escaped, some of them are capable to impair antigen processing and presenting pathway, 
or suppress the induction of pro-inflammatory cytokines, resulting in deficiency of 
immune detection (11). At this stage, the immune system would help rather than inhibit 
tumor growth, notably by promoting the tumor cell survival and infiltration. In this regard, 
the mostly known switch in the immune system is alternative activated macrophages. 
Macrophages are likely to differentiate or switch from their immunosurveillance 
phenotype to an immunosuppressive phenotype, which would promote rather than 
suppress tumor growth. The immunosuppresive macrophages phenotype presented in 
tumor tissues are referred to as tumor-associated macrophages (TAMs), which produce 
less inflammatory cytokines, promote Th2 T-cell responses, have poor antigen presenting 
capability, suppress T-cell proliferation and increase local angiogenesis (2, 11-16). It 
should be noted that in most clinical cases, patient prognosis in solid tumors is generally 
correlated inversely with TAM density. In the PyMT mouse model of breast cancer (17, 
18), higher populations of macrophages are recruited at the adenoma intraepithelial stage 
when the tumors progressing to malignancy (4, 18-21). There is also strong evidence 
shown the association between poor survival and increased macrophage density in 
thyroid, lung, and hepatocellular cancers (22-24).  
 
M2 phenotype macrophages influence multiple steps in tumor development, 
including tumor growth, invasion, angiogenesis and suppression of antitumor immune 
response by releasing proteases, angiogenic factors, and cytokines (4, 12, 25). Studies 
have shown that TAMs express a number of factors, which stimulate tumor cell 
proliferation and survival, including epidermal growth factor (EGF) (26, 27), platelet-
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derived growth factor, TGF-β1, hepatocyte growth factor, and basic fibroblast growth 
factor (bFGF; 28). Macrophage synthesized EGF and CSF-1 (also known as M-CSF) are 
also found to stimulate tumor cell invasion. Results from co-cultured experiments with 
tumor cells and macrophages indicated that tumor cell invasion was stimulated by EGF 
and CSF-1(12, 26). TAMs also release a wide range of cytokines to stimulate tumor 
angiogenesis, including VEGF, TNF-α, IL-8, bFGF and a broad array of angiogenesis-
modulating enzymes, as MMP-2, MMP-7, MMP-9, MMP-12, and cyclooxygenase-
(COX-2; 29-31), leading to the formation of new, mature blood vessels (11). 
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Figure  3. 2 The dual role of macrophages in tumor tissue. 
    (Chrystelle Lamagna, Michel Aurrand-Lions and Beat A. Imhof J Leukoc Biol, 2006.) 
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Figure  3. 3 The roles of different subpopulations of TAMs in tumor progression. 
                  (Claire E. Lewis and Jeffrey W. Pollard. Cancer Res, 2006 ) 
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3.1.3 The recruitment of macrophages into the tumor mass  
 
Both M1 and M2 phenotype macrophages and their monocyte progenitors are 
recruited to the tumors from the blood circulation after released from bone marrows.  
Macrophages may also migrate to tumors from the surrounding tissue (32). Most of 
monocytes, which become TAMs in the tumor, are attracted into the tumor mass by the 
chemokines and cytokines in tumor microenvironment. CCL2 is firstly identified as a 
tumor-derived chemotactic factor (33). Early work shows that CCL2 induces recruitment 
of monocytes into fibrosarcomas to enhance tumor growth (34). The low-level expression 
of CCL2 by tumor cells correlates with a reduced monocyte infiltration and its absence is 
associated with increased survival in cervical cancer patients. In addition, in the model of 
choroidal neovascularization, reduction of the number of infiltrating macrophages is 
observed with inactivation of CCR2, the receptor of CCL2 (35). With its essential role in 
macrophage recruitment, CCL-2 is found to be overexpressed in a wide range of cancers 
(36) and is associated with poor prognosis in breast, colorectal, and thyroid cancers (37-
40).  
 
Moreover, it is well established that M-CSF is also a critical factor implicated in 
the recruitment of macrophages into neoplastic tissues (41). It has been shown that 
infiltration of monocytes into tumors is reduced markedly in the absence of M-CSF, 
resulting in delayed angiogenesis and tumor progression. Overexpression of M-CSF is 
associated with poor prognosis in breast, ovarian, endometrial, prostate, hepatocellular, 
and colorectal cancer (36, 42-47). Tumor growth factor (TGF-β) has also been reported 
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to be associated with the presence of macrophages within tumors. Studies revealed that in 
patients with gallbladder cancer, expression of TGF-β increases along with cancer 
progression and strongly influence angiogenesis and macrophage infiltration, which 
contributes to tumor proliferation (48, 49).  
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Figure  3. 4 Macrophage recruitment in tumor tissues by CSF-1 and CCL2. 
                                  (Binzhi Qian and Jeffrey W. Pollard. Cell, 2010) 
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3.2 Materials and Methods 
 
 3.2.1 Allograft tumor models 
 
Allograft mouse tumor systems, also known as syngeneic models, consist 
of tumor tissues derived from the same genetic background as a given mouse strain. 
Since the cancer tissues and the host mouse share genetic background, the transplant is 
not rejected by the host’s immune system. In this experiment,  P53-/-, RL-/- fibrosarcoma 
cells were injected subcutaneously into RNase L wild type  and knocked-out C57BL/6 
mice, respectively with 4.3x106 cells for each mouse. Mice with the same gender and age 
were used in this experiment. Tumors were formed and continued to grow for 3 weeks 
and then excised.   
 
3.2.2 Immunofluorescence staining 
 
Immunofluorescence staining is one specific example of immunohistochemical 
staining, which utilize the enzyme, such as peroxides, conjugated on antibodies to 
catalyze a color-producing reaction, and therefore allows visualization of the location of 
biomarkers or proteins in tissue. In immunofluorescence staining, a fluorescent dye, 
instead of peroxides, is conjugated with an antibody to visualize specific antigens.    
In this experiment, tumor tissues isolated from mice were immediately fixed in 10% 
formalin, embedded with paraffin and sectioned at 5 μm (Department of Oral Pathology, 
Case Western Reserve University School of Dental Medicine).  Tumor tissue section 
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were de-paraffinized in xylene for 3 times, hydrated with serially diluted ethanol (90%, 
70%, 50%, 5 min each), and then washed with distilled water for 20 min. Antigens were 
retrieved by incubating in a sodium citrate buffer at 95℃ for 20 min. This process is 
necessary because, fixatives used to preserve cellular morphology, also causes protein 
cross-linking, resulting in the inability of some protein epitopes to bind complementary 
antibodies. Antigens retrieve could improve staining by modifying the molecular 
conformation of ‘target’ proteins. Tissue sections were first blocked with 10% donkey 
serum for 1hr, then incubated with goat anti-mouse F4/80 polyclonal antibody overnight 
at 4℃, which followed by incubation with AlexFluor488 (Cell signaling, MA) 
conjugated donkey anti-goat IgG antibody for 1 h. Nuclei were visualized with DAPI 
(Vector Laboratories Inc., Burlingame, CA). Isotype controls were simultaneously 
performed using isotype-matched IgG, corresponding to primary antibody. 
Immunofluorescent images were generated using a Leica DMI 6000B automated inverted 
fluorescence microscope.  
     
3.2.3 Determine cytokine expression in tumor tissues with ELISA 
 
As described in 2.2.4, ELISA was used to assess the production level of CCL2, 
IL-10, and TGF-β in tumor tissues from both RNase L wild type and knocked-out mice. 
ELISA kits (eBioscience, CA) were used for this assay.  
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3.2.4 Macrophage depletion  
 
Clodronate liposome was used to experimentally deplete macrophages. 
Clodronate is captured in liposome, which will be ingested and digested by macrophages.  
Clodronate is then released out and accumulated in macrophages till a certain 
concentration to induce macrophage apoptosis. Using clodronate liposome to deplete 
macropahges has been applied in various models of autoimmune disease, transplantation 
and tumor research.  
 
In this experiment, clodronate liposome was used to deplete macrophage in both 
wild type and RNase L knocked out mice. Clodronate was purchased from Roche 
Pharmaceuticals (Germany) and was encapsulated in liposomes by Encapsula 
Nanosciences (Nashville, TN). Control liposomes containing phosphatidylcholine and 
cholesterol without clodronate was injected into the control groups. Four mice were used 
in each group, with P53-/- RL-/- cell injection. Mice were injected with clodronate 
liposome 0.2mg Intraperitoneally (i.p.) 3 days before carcinoma cell injection. Carcinoma 
cells were cultured and suspended in PBS with concentration at 2x106/100μl. Mice with 
the same gender and age were injected with 100μl cell solution subcutaneously, which 
followed by another 3 times clodronate liposome (0.1mg) injection on day1, 2,and 6 to 
continuously deplete macrophages (Figure 3.4) . In control group, mice were received 
with the same volume of control liposomes and carcinoma cells.  To evaluate the effect of 
clodronate liposome, tumors from mice were stained with an anti F4/80 polyclonal 
75 
 
antibody and analyzed under a microscope as described in immunofluorescence assay 
(3.2.2).  
 
 
 
     
Figure 3. 5 Time scale for macrophage depletion experiment. 
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3.3 Results 
 
3.3.1 RNase L promotes tumor growth  
 
Based on previous results that RNase L impacts on macrophage phagocytosis and 
migration ability, we were prompted to hypothesize whether RNase L would suppress 
tumor growth via its modulation on macrophage innate immunity. To test our hypothesis, 
we used an allograft tumor model. A fibrosarcoma cell line with mutation of P53 gene 
were injected subcutaneously into gender and age matched RNase L+/+ and RNase L-/- 
mice. P53 is a tumor suppressor gene, which mutation results in severely reduced tumor 
suppression. After implantation of tumor cells, tumor growth was monitored and tumors 
were excised from mice after 3 weeks.  
 
Surprisingly, tumors grew in RNase L +/+ mice were significantly larger than that 
in RNase L-/- mice (Figure 3.5A). RNase L-wild type mice with carcinoma cells injection 
produced, on average, 3-fold greater weight of tumors than that in RNase L-/- mice 
(Figure 3.5B). This observation was consistent in both female and male mice. The results 
suggest that RNase L promotes rather than suppresses tumor growth, which was opposite 
as we expected. It has been reported that although classically activated macrophages are 
important effectors in anti-tumor immunity, macrophages in tumors are more likely to 
enhanced tumor progression in the majority of experimental and clinical cases (4, 11, 12). 
Thus, our results implicated that RNase L may promote tumor growth through impacting 
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M2 macrophage function. 
 
 
 
 
 
 
     
Figure 3. 6 RNase L promotes P53-/- RL-/- tumor growth in mice. 
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3.3.2 RNase L affects macrophage recruitment in tumor growth  
 
It should be recognized, however, that although classically activated macrophages 
are effectors in anti-tumor immunity, alternatively activated TAMs enhanced tumor 
progression to malignancy. Macrophage polarization and recruitment in a tumor are 
important for tumor cell survival, polymerization, and invasion (4, 12).  Based on the 
current results, we next determined macrophage distribution in tumor tissues. We 
performed immunofluorescence staining to detect macrophage presence in tumor tissues 
from RNase L +/+ and RNase L-/- mice with P53-/- RL-/- cell injection. Tumor tissue 
sections were stained with an antibody that specifically recognizes the macrophage 
marker F4/80 and nuclei were stained with DAPI. Interestingly, we observed clear 
difference of macrophage presence in the tumors from RNase L+/+ and -/- mice.  As shown 
in figure 3.6A, macrophages were observed only to gather in tumors from RNase L+/+ 
mice. By contrast, this accumulation of macrophages was not detected in tumors from 
RNase L-/- mice. This result indicated that RNase L contributes to macrophage 
accumulation in tumor tissues. Because in most clinical and experimental models, 
macrophages in tumor tissue promote tumor cell growth and tumor progression, the effect 
of RNase L on macrophage recruitment and accumulation may explain the outcome.   
 
To confirm that less extent of macrophage recruitment in tumors is resulted from 
deficiency of RNase L, we investigated the RNase L protein level in tumor tissues. As 
shown in Figure 3.6B, with the same P53-/- RL-/- carcinoma cell injection, tumors from 
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RNase L +/+ mice still expressed a high level of RNase L, whereas expression of RNase L 
in tumors from RNase L -/- mice was significantly reduced.  
 
 
 
 
 
 
Figure 3. 7 RNase L facilitates macrophage recruitment in tumors. 
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3.3.3 RNase L modulates tumor microenvironment  
 
The immunofluorescence staining results demonstrated that macrophage 
recruitment was remarkably reduced in the mice with deficiency of RNase L. It is well 
established that macrophage infiltration, differentiation and activation in tumor tissues 
are mainly regulated by tumor microenvironment, including various cytokines and 
chemokines. As described in 3.1.2 and 3.1.3, M-CSF, IL-4 and IL-13 are known to 
induce M2 type macrophage polarization, and CCL2, M-CSF, TGF-β and VEGF secreted 
in tumors are important to attract macrophage into tumor tissues.  To determine the 
involvement of RNase L in tumor microenvironment, we evaluated the expression level 
of some factors important for macrophage recruitment in tumors. Our results showed that 
there was a twofold decrease of CCL-2 expression in tumors from RNase L-deficient 
mice, compared to that in the tumors from RNase L wild type mice (Figure 3.7A). 
Similarly, the expression of TGF-β and M-CSF was positively associated with the level 
of RNase L in the tumors. The higher RNase L was expressed, the more TGF-β and M-
CSF were produced (Figure 3.7B, C). The results implicated that RNase L was involved 
in regulating the production of CCL2, M-CSF, and TGF-β in tumors, as a result, 
macrophage recruitment in tumors from RNase L deficient mice was reduced..  
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Figure 3. 8 RNase L regulates CCL2, M-CSF, and TGF-β expression. 
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3.3.4 Macrophage depletion  
 
Previous data suggested that RNase L is required for macrophage recruitment in 
tumor tissues, and indicated that RNase L may contribute to tumor growth by increasing 
macrophage presence. To provide further evidence about the role of macrophages 
population in P53-/- RL-/- tumors, macrophages were experimentally depleted in vivo by 
injecting mice with liposome encapsulated clodronate. Clodronate liposome causes 
transient depletion of macrophages in the liver and spleen within 24 hrs and the 
population is not restored in 2 weeks thereafter (50).  In this study, RNase L +/+ and -/- 
mice received clodrosome or control liposome 3 days prior to tumor cell inoculation,  and 
1, 2, 6 days post injection (51-53). Mice were sacrificed 3weeks later, and the tumors 
from clodronate liposome treated mice were significantly smaller than that from the 
control group (Figure 3.8). Depletion of macrophages effectively reduced tumor growth 
in both RNase L- wild type and -deficient mice, while there was no effect from control 
liposome treatment. In addition, the difference of size and weight of tumors between 
RNase L+/+ and RNase L-/- mice after macrophage depletion treatment was similar, 
suggesting that the impact of RNase L on tumor growth might be mainly from the effect 
of RNase L on macrophages.  
 
To determine whether clodronate liposome effectively eliminated macrophages, 
tumor sections were incubated with antibodies specific for the macrophage antigen F4/80.   
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As shown in Figure 3.9, the infiltration of macrophages in tumors from RNase L +/+ mice 
was significantly decreased, confirming that macrophages were efficiently depleted.  
 
 
 
 
 
Figure 3. 9 Tumor growth after macrophage depletion. 
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Figure 3. 10 Clodronate liposome depleted macrophages in tumors. 
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3.4 Discussion 
 
Based on previous findings that the role of RNase L plays in macrophages, we 
were prompted to hypothesize whether RNase L suppresses tumor growth via its 
modulation of macrophages endocytic and migration ability. Carcinoma cell lines with 
mutation of P53 gene were used to test our hypothesis. However, we found that with 
injection of P53-/- RL-/- carcinoma cells, tumors grew significantly bigger in RNase L +/+ 
mice compared to that in RNase L -/- mice.  The results suggested that RNase L promotes 
rather than suppresses tumor progression.  In recent years persuasive evidence has 
emerged that, in majority of clinical cases and experimental models, macrophages could 
enhance tumor cells invasion, proliferation and survival (4, 11, 12). Bingle et al. reported 
that, in over 80% of studies, macrophage density was positively correlated with poor 
patient prognosis (54). It has been firmly established that monocytes extravasate into 
tumor tissues and differentiate into a distinct type of macrophages termed tumor-
associated macrophages (TAMs) (4). TAMs show greatly reduced antitumor functions, 
and are possibly driven by tumor microenviroment with tumor-derived molecules as IL-6, 
IL-8, CCL2 and PGE2. Furthermore, the tumor promotion activity of TAMs depends on 
the expression of a number of growth factors and cytokines, including VEGF, TNF-α, 
IL-8, and basic fibroblast growth factor (bFGF), which could stimulate tumor growth and 
angiogenesis (11, 12, 55).  To definitely establish that macrophages promote P53-/- RL-/- 
carcinoma cell proliferation, we adapted a classical protocol in which clodronate 
liposome was used to deplete macrophages in a mouse model. Consistent with other 
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results for TAMs, we demonstrate that P53-/- RL-/- tumor growth in our mouse model was 
largely reduced in the absence of macrophages.   
 
 
Collectively, these data indicate that RNase L does not contribute to tumor growth 
through its modulation of macrophage innate immunity, but may rather through its effect 
on macrophage density.   Using immunofluorescence staining, we observed sparse 
macrophages presenting in tumors from RNase L-/- mice compared to  that in RNase L+/+ 
mice, suggesting that RNase L is indeed required for macrophage recruitment. Consistent 
with tumor size and macrophage recruitment results, we observed a reduction expression 
level of M-CSF, TGF-β, and CCL2 in tumors from mice that lack RNase L compared to 
the wild type mice, which indicates that suppressed tumor growth in RNase L-/- mice at 
least in part is attributed to impaired production of cytokines and chemokines.  Our 
studies revealed for the first time the promotion role of RNase L in tumor growth, which 
maybe owing to its regulation on macrophage presence and efficient cytokines release. 
Nevertheless, it remains to be determined whether our findings extend to other carcinoma 
cell lines.  
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CHAPTER IV 
RNASE L REGULATES CYCLOOXYGENASE (COX)-2  
PROMOTER ACTIVITIES 
 
 
4.1 Introduction of cyclooxygenase (COX)-2  
 
COX-2 is a unique enzyme, catalyzing the conversion of an arachidonic acid to 
prostaglandin G2 (PGE2), which play an essential role in inflammation pathway. There 
are two known forms of cyclooxygenase, COX-1 and COX-2, which are encoded by two 
genes (1, 2).  It is known that COX-1 is wildly distributed in all cells, constitutively 
expressed in the majority of tissues and displays characteristics as a housekeeping gene 
(3).  However, another isoform, COX-2 is highly expressed under stress, especially in 
response to growth factors, cytokines and pro-inflammatory molecules (4).  COX-2 has 
been widely studied since it is a target of non-steroidal anti-inflammatory drugs 
(NSAIDs), which exert their anti-inflammatory function through inhibiting COX-2 
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activity to release pain (4). Studies found that COX-2 expression can be stimulated in 
vivo by wounding and inflammation (5, 6) and in vitro COX-2 could be induced by 
lipopolysaccharide (LPS) through a Tpl2 dependent pathway (7-9).  
 
The functional relationship between the inflammation response and cancer is 
widely recognized. Inflammatory events can create a local microenvironment capable of 
promoting tumor growth progression. As an essential mediator of inflammation and pain, 
COX-2 also participates in the processes of carcinogenesis. COX-2 is overexpressed at 
sites of inflammation and tumor tissues, where COX-2 was found to enhance cell motility 
and invasiveness (10). Moreover, COX-2 is strongly associated with macrophages in 
inflammation and tumorigenesis and highly expressed in macrophages, normally with a 
strong correlation to enhanced macrophage migration and infiltration. In mouse cornea 
tissues, infiltrating macrophages near the IL-1β induced neovasculature were also COX-2 
positive, and a COX-2 inhibitor was found to reduce macrophage infiltration in Lewis 
lung carcinoma cells (11). In Alzheimer’s disease brain, COX-2 positive macrophages 
were found to infiltrate perivascular spaces and neuropil (12). Studies by Masatoshi Hori 
et.al showed that in RAW264.7 macrophages, COX-2 inhibitors completely inhibited 
macrophage migration at 4 hrs (13).  
 
Based on our previous results that RNase L is necessary for the induction of 
COX-2 by LPS in fibroblasts and adipocytes, together with the strong association of 
COX-2 with macrophage infiltration and tumorigenesis, the effect of RNase L on COX-2 
in macrophages was assessed.  
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Figure 4. 1 The current COX concept. 
                                                    (David Gotlieb, 1999) 
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4.2 Materials and Methods  
 
4.2.1 Determine COX-2 protein level in macrophages by Western Blot.  
 
All western blot experiments performed here were using SDS-PAGE and wet 
(tank) transfer.  
To determine the effect of RNase L on COX-2 expression in macrophages, 
BMMs from both RNase L wild type and knocked- out mice were treated with LPS 
(1μg/ml) or M-CSF (10ng/ml) for 14hrs, respectively. Western Blot was performed as 
previous described with a primary antibody specific to COX-2 (1:1000 dilution, Cayman 
Chemical, MI) and HRP-conjugated anti-rabbit IgG (Cell signaling, MA) as a secondary 
antibody.  
 
4.2.2 RNA extraction and real-time polymerase chain reaction (RT-PCR)  
 
Real-time polymerase chain reaction (qRT-PCR), also known as quantitative PCR 
is developed based on PCR, which is the most powerful technology in the laboratory to 
measure target DNA. Various fluorescent reporters were used in qRT-PCR, and a qRT-
PCR machine could record the amount of PCR products by detecting fluorescence 
throughout a reaction. The fluorescent signal increases in proportion to the amount of 
PCR product. In this experiment, a non-sequence specific fluorescent intercalating agent, 
SYBR-green, was used as the fluorescent reporter. SYBR green is a fluorogenic minor 
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groove binding dye that exhibits little fluorescence when in solution but emits a 
detectable fluorescent signal upon binding to dsDNA (14; Figure 4.2). 
 
In experiment, total cellular RNA was extracted from macrophages with TRIzol 
Reagent. COX-2 mRNA levels were detected using qRT-PCR with a one-step SYBR 
green qRT-PCR kit (Quanta Biosciences, MD) according to the manufacturer’s 
instruction. COX-2 primers were synthesized by Integrated DNA Technologies, Inc. 
Primers were also synthesized to amplify the cDNA encoding GAPDH as a control.   
RNA concentration was determined and 100ng total RNA was firstly reverser transcript 
to cDNA at 50°C for 10 min, which followed by 5 min Taq activation at 90°C, and 30 
PCR cycles including 10 sec at 94°C and 30 sec at 60°C within the StepOne Plus Real-
Time PCR system (Applied Biosystems, CA). SYBR signals and mRNA quantities were 
analyzed by using StepOne software.  
 
 
 
 
 
 
 
 
 
 
100 
 
 
 
 
 
 
 
 
 
                              
Figure 4. 2 SYBR Green during PCR amplification. 
                     (Dean Fraga, et al. Curr. Protoc. Essential Lab. Tech., 2008) 
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4.2.3 Transfection and reporter assays 
 
The reporter gene assay is used in the laboratory to investigate the genetic 
regulatory elements such as promoters, or transcription factors which influence the 
activity of regulatory elements. A luciferase reporter assay is one reporter gene assay, 
which is widely used because of its high sensitivity. In a reporter construct, the promoter 
of gene of interest was constructed to control one luciferase gene. By adding luciferase 
substrate, luciferase reporter activity could be measured by produced light signals (Figure 
4.3). 
 
The COX-2 promoter (-860/+127)-pGL3 luciferase reporter construct provided by 
Dr. Narkunaraja Shanmugam was transfected into RNase L+/+ and -/- MEFs by using 
lipofectamine 2000 (Invitrogen, CA). After transfection, LPS (1μg/ml) was added to 
induce COX-2 promoter activity for 14hrs. Transfection efficiency was monitored by 
simultaneous transfection of galactosidase constructs and the relative luciferase value 
(RLV) was calculated by the ratio of luciferase activity divided by the activity of 
galactosidase. Groups only with COX-2 promoter transfection or LPS treatment and 
control group without any treatment were simultaneously performed. After adding the 
luciferase assay reagent, light was produced and measured in a Wallac 1420 Multilablel 
Counter (Perkin Elmer, MA). Experiments were repeated twice.  
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Figure 4. 3 Schematic of the luciferase reporter assay. 
(Thermo Fisher Scientific, Inc) 
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4.3 Results 
 
 
4.3.1 RNase L regulates the induction of COX-2 by LPS and M-CSF in BMMs  
 
Based on our previous results that RNase L is necessary for the induction of 
COX-2 by LPS in fibroblasts and adipocytes, we were prompted to determine the role of 
RNase L in COX-2 in macrophages.  As shown in Figure 4.4, RNase L deficiency 
significantly attenuated the induction of COX-2 expression in response to M-CSF and 
LPS. Consistent with our earlier data, the results indicated RNase L is essential in the 
induction pathway of LPS and M-CSF on COX-2 expression. 
 
4.3.2 RNase L regulates induction of COX-2 promoter activity by LPS 
 
Furthermore, COX-2 mRNA amount in mouse embryonic fibroblasts (MEFs) was 
determined by real time-PCR, and similar to the protein expression, RNase L-/- MEFs 
failed to induce COX-2 transcription level in response to LPS, which suggests that the 
effect of RNase L on COX-2 stimulation by LPS is mainly at the level of transcription 
(Figure 4.5). Luciferase reporter assay was subsequently designed to address the role of 
RNase L in regulating the activity of the COX-2 promoters. RNase L -wild type and -
deficient MEFs were transfected with a reporter construct containing a luciferase gene 
under the control of COX-2 (-860/+127) promoter. β−galactosidase vectors were 
simultaneously transfected to equalize different transfection efficiency. After 14 hrs 
treatment of LPS (1μg/ml), the results showed that LPS induced COX-2 promoter 
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activity, whereas RNase L-deficient cells were greatly resistant to the induction of COX-
2 promoter activity by LPS (Figure 4.6).  
 
 
 
 
        
Figure 4. 4 RNase L regulates the induction of COX-2 by LPS and M-CSF. 
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Figure 4. 5 RNase L regulates COX-2 mRNA transcription. 
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Figure 4. 6 RNase L regulates induction of COX-2 promoter activity by LPS. 
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4.4 Conclusion  
 
As an essential mediator in inflammation, COX-2 was previously found to require 
RNase L for its expression in response to LPS in fibroblast cells. Here it is further 
confirmed that in RNase L deficient BMMs, the induction of COX-2 expression in 
response to LPS has been greatly inhibited. Moreover, our studies demonstrated that the 
sites where RNase L modulates the induction of COX-2 by LPS are located in COX-2 
promoter ranging from -860 to +127. Studies from other groups indicated that COX-2 
expression level in macrophage cells may be correlated with their migration ability and 
their infiltration in inflammation sites and tumor tissues. Moreover, studies implicated 
that overexpression of COX-2 was strongly associated with tumor progression. 
Consistent with those findings, RNase L also showed efficient activity to promote 
macrophage infiltration and tumor growth, which suggest that the promotion function of 
RNase L on macrophage migration and tumor proliferation may in part due to its 
regulation on COX-2 expression. Further studies need to investigate the detailed 
molecular mechanism by which RNase L regulates the expression of COX-2.  
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CHAPTER V 
MECHANISM INVESTIGATOIN OF ONE  
ANTI-CANCER DRUG CANDIDATE 
 
 
5.1. Introduction 
 
5.1.1 COX-2 inhibitor Nimensulides analog Compound 2 
 
Compound 2 is a potent anti-cancer agent structurally derived from the COX-2 
inhibitor nimesulide (1). Numerous studies have demonstrated the anti-cancer activity of 
nimesulide. However, the nimesulide concentrations used in these studies ranged from 
200 to 500µM, which greatly exceeded the concentration necessary to inhibit COX-2 
activity (2-7). This line of reasoning suggests that nimesulide targeted other pathways in 
order to achieve anti-cancer activity, and blockage of these pathways required much 
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higher concentrations. This supported the hypothesis that nimesulide inhibited cancer cell 
growth and induced apoptosis independent of its effects on COX-2(3, 4, 8). Structural 
modifications were made to eliminate the COX-2 inhibitory activity and the 
hepatotoxicity, but it was not clear if the anti-cancer activity would be improved. After 
extensive investigations, the first generation non-COX-2 active nimesulide anti-cancer 
derivative JCC76 was synthesized (9, 10, 11). It inhibited SKBR-3 breast cancer cell 
growth with an IC50 of 1.38µM, which was about 100 fold more active than nimesulide. 
Furthermore, compound 2 was recently developed based on compound 3 (JCC76) and 
has demonstrated greater anti-cancer potency (1), with IC50s of 0.1 µM to 0.5 µM to 
inhibit cancer cell growth. However, the specific molecular targets of compound 3 and 2 
were still unclear. Therefore, the major scheme in this experiment was to identify the 
molecular targets and to investigate the biologic function of Compound 2 on it molecular 
targets.   
 
5.1.2 Tubulin as a target for anti-cancer drugs  
 
Tubulin-containing structures are important for many important cellular functions, 
including chromosome segregation during cell division, intracellular transport, 
development and maintenance of cell shape, cell motility, and distribution of molecules 
on cell membranes (12). The rapid growth of cancer cells leads to their high dependence 
on tubulin polymerization/depolymerization, which makes tubulin a good target for anti-
cancer drug development. Paclitaxel (Taxol), the representative tubulin inhibitor 
approved by the FDA in 1992 for cancer treatment, is one of the most powerful 
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chemotherapeutic agents currently in use. Taxol binds to tubulin and results in its 
precipitation and sequestration, which interrupt many important biological functions of 
cancer cells that depend on a dynamic tubulin polymerization and depolymerization 
process (13). This explains the high potency and efficacy of Taxol in fighting cancer. 
 
Besides Taxol, FDA also approved other tubulin inhibitors with complex 
structures for cancer treatment including epothilone analogs, vinca alkaloid analogs, and 
halichondrin analogs.  Treatment with tubulin inhibitors has led to improvement in the 
duration and quality of life for many cancer patients (14). However, the majority of them 
eventually develop progressive disease after initially responding to the treatment (15-17). 
Drug resistance of most tubulin inhibitors represents a major obstacle to overcome in 
order to improve the long-term response and survival of cancer patients. In addition to the 
resistance issue, neurotoxicity is one of the major side effects of the tubulin inhibitors 
derived from complex natural products, which affects the quality of life of cancer patients 
(18-20). Furthermore, low oral-bioavailability limits the convenient oral drug 
administration (21). There is an urgent need to develop new tubulin inhibitors with fewer 
side effects, good oral bioavailability, and less prone to the development of resistance.  
 
5.2 Materials and Methods 
 
5.2.1. Biotin- neutravidin Pull-Down Assay 
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SKBR-3 cells (1.0 × 107) were disrupted in a RIPA lysis buffer and sonicated, 
with freshly added protease inhibitor cocktail (Roche). The cell lysate was incubated with 
biotin-conjugated compound 2 probe, at room temperature for 1h. The mixture was 
further incubated with equilibrated and packed neutravidin resin in columns at room 
temperature for 30 min, which followed by centrifugation and five times repeated 
washing with binding buffer to wash out non-binding proteins (Figure 5.1 and 5.2). The 
pull down assay was performed according to the protocol of neutravidin (Thermofisher). 
The protein interacted with the biotinylated compound 2 was cleaved from the beads by 
eluted with binding buffer containing compound 2. The resin was also collected and 
boiled with SDS buffer to determine the leftover proteins. The elution solution was boiled 
with 1x loading buffer (100 mmol/L DTT plus bromophenol blue) for 5 minutes and then 
electrophoresed on a 10% SDS-polyacrylamide gel. The resulting gel was visualized with 
silver stain kit (For Mass Spectrometry-Compatible Silver Staining Kit, Invitrogen, CA).      
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Figure 5. 1 Compound 2 probe immobilized with Biotin-neutravidin. 
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Figure 5. 2 Illustration of Biotin- neutravidin Pull-Down Assay. 
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5.2.2. Peptide Analysis of the compound 2-binding Protein via Mass Spectrometry 
 
This process is accomplished by Dr. Kerri M. Smith. Bands visualized by silver 
staining were cut and transferred to 0.65 mL siliconized tubes (National Scientific Supply, 
Claremont, CA). The silver reagent was removed with the denature reagents (Invitrogen, 
CA).   Proteins were in-gel digested by trypsin (Sequencing Grade, Modified; Promega, 
Madison, WI).  The protein digest was reconstituted in 20 μL of 0.1% (v/v) 
trifluoroacetic acid prior to LC-QTOF/MS analysis. Peptide separation was carried out 
using 10-μL sample injection at 50 μL/min flow rate on a Vydac® Protein & Peptide C18 
(5 μm, 300Å, 1 mm × 150 mm) column (Grace Discovery Sciences, Deerfield, IL) 
proceeded by an inline filter (0.5 μm pore) (Upchurch Scientific, Oak Harbor, WA).  The 
gradient elution profile consisted of 1% of mobile phase A for 5 min, then brought to 
60% of mobile phase B over 90 min, and followed by 90 % of mobile phase B for 8 min. 
The total run time was 105 min. Mobile phase A was 0.1 % (v/v) formic acid in HPLC-
grade ddH2O, and the mobile phase B was 0.1 % (v/v) formic acid in HPLC-grade 
acetonitrile. Peptide detection was done using the positive information-dependent-
acquisition (IDA) mode of AB Sciex QStar™ Elite Q-TOF mass spectrometer (AB Sciex, 
Foster City, CA). Data acquisition was performed using AB Sciex Analyst QS (v. 2.0).  
Protein identification through peptides matching was accomplished using Mascot MS/MS 
Ions Search (http://www.matrixscience.com).  
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5.2.3. Western blot 
 
To confirm the identity of protein targets which have been discovered in 
neutravidin resin pull-down assay, Western Blot was conducted. Primary antibody 
specific to tubulin or Hsp27 (Cell signaling, MA) were incubated over night at 4°C, 
which followed by HRP-conjugated anti-rabbit IgG or anti-mouse IgG (Cell signaling, 
MA) incubation at room temperature for 1h. Membrane was incubated in ECL plus 
reagent (GE health, OH) and then exposed to hyper film.  
 
To determine the effect of compound 2 on Hsp27 phosphorylation, SKBR-3 cells 
were treated with 0.2μM, 0.5μM and 1μM of compound 2, 50nM, 100nM Nocodazole 
(Sigma, MO), and 0.5μM, 1μM KRIBB3 (Sigma, MO), respectively for 24 h. Protein 
lysis buffer (1% Triton X-100, 10 mM Tris⋅HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 
1 mM Na3VO4) optimal to phophorylated protein were prepared.  Extracted proteins from 
SKBR-3 cells were loaded on 12% SDS-polyacrylamide gel, which allows a better 
protein separation. Antibody specific to phosphorylated Hsp27 (Ser 78, Cell signaling, 
MA) was used to blot membrane, and secondary antibody anti-rabbit IgG was blotted 
thereafter. Hsp27 and Actin antibodies were also used to confirm equal loading amount. 
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5.2.4. Compound 2 binding to tubulin and Hsp27 
 
10μM bovine brain tubulin (Cytoskeleton, Denver, CO) or Recombinant 
Hsp27(ProSpec, East Brunswick, NJ) were incubated with 2μM biotinylated compound 2 
in binding buffer in a total volume of 500 μL for 1h at room temperature before loading 
onto pre-packed neutravidin resin column and further incubated for 30min. The resin was 
washed with 500μL of binding buffer 5 times and 2 times with buffer containing 
compound 2. For the colchicine, Taxol and compound 2 probe competition experiments, 
tubulin was pre-incubated with 10 μM colchicine or Taxol at room temperature for 1h 
before the incubation with the probe. The samples were fractionated by SDS-PAGE and 
examined with western blot assay. 
 
5.2.5. Tubulin Polymerization Assay 
 
Microtubule-associated protein-rich tubulin (2mg/ml, bovine brain, Cytoskeleton, 
CO) in buffer containing 80mM PIPES (pH 6.9), 2mM MgCl2, 0.5mM EGTA, and 5% 
glycerol, were placed in cuvettes 200ul/assay, and incubated respectively with DMSO, 
0.5μM and 1μM of compound 2, 5μM of compound 3, and 3μM of nacodazole. 
Polymerization was started by adding 1mM GTP and incubation at 37°C, and followed 
by absorption readings at 340nm with Varian Cary 50 Series Spectrophotometer (every 5 
sec/min 0- min 3, every 10 sec/ min 3- min 5, every 30 sec/ min 5- min 10, and every 60 
sec/ min 10- min 17).  
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5.2.6. Indirect Immunofluorescence staining 
 
SKBR-3 cells were transferred in chamber slides and cultured to 70% confluence, 
and then incubated with 0.5μM or 1μM of compound 2 respectively for 12 h and 24h. In 
parallel, the cells without treatment were used as negative control, and cells treated with 
0.05μM nacodazole for 12 and 24 hrs were used as positive control. Cells receiving 
different treatments were fixed in 4% paraformaldehyde for 10 min at room temperature 
and then permeabilized with 0.2% Triton X-100 for another 10 min. After blocking with 
2% goat serum for 45 min at room temperature, cells were incubated with biotinylated 
anti-tubulin antibody (1:200, Molecular Probes, OR) overnight at 4 °C. After washing 
with PBS, cells were then stained with Alexa Fluor 488 streptavidin (1:1000, Invitrogen, 
NY) for 45 min at room temperature, which followed by mounting with antifade reagent 
(ProLong Gold antifade reagent, invitrogen, NY). Fluorescently stained cells were 
analyzed with Leica TCS SP2 fluorescence microscope.   
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5.3 Results 
 
5.3.1. Affinity purification of Compound 2-bound proteins 
 
We hypothesized that compound 2 bound to certain proteins to achieve its anti-
cancer activity. We mixed compound 2 probe with SKBR-3 breast cancer cell lysate, in 
order to allow specific binding proteins to attach to the compound 2 moiety of the probe. 
For the protein isolation, the biotin moiety of the probe was bound to the neutravidin 
resin to immobilize the probe. After extensive washing with binding buffer, the non-
binding proteins were eluted. Then compound 2 was used as a competing agent to wash 
the immobilized probe, and the proteins specifically binding to the probe at the 
compound 2 domain were pulled out. The main procedure is described in Figure 5.1. We 
next examined the molecule weight of the binding proteins using SDS/PAGE and stained 
the gel with silver staining reagent (Figure 5.3). Lane 2 is the cell lysate, lane 3 is the 
final elution solution. Lane 5 is the binding buffer with compound 2 (25µM) as elution 
solution. Lane 6 is binding buffer with compound 2 (50µM) as elution solution, and lane 
4 is the resin boiled with SDS buffer. The results suggest that compound 2 was not 
competitive enough to pull all the proteins out of the probe, and the resin with the probe 
still held a good amount of proteins. It is also possible that the competition experiment 
was finished on the resin packed column and only lasted 30 mins, which led to less 
effective competition. There are seven visible protein bands that can be identified on the 
gel. Protein a and b have molecular weight above 110 KD, protein c has a molecular 
weight about 80 KD, protein d, e and f have molecular weight about 55 to 60 KD, and 
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protein g has a molecular weight about 28 KD. Apparently, d and e are the major proteins 
bound to compound 2, the other proteins are relatively minor. However, it is too early to 
speculate which protein(s) is (are) the role player(s) at this stage. Minor attached proteins 
are not less important than the highly binding proteins. We will identify all the visible 
proteins on the gel in next step. 
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Figure 5. 3 Affinity isolation of compound 2-binding proteins. 
The last buffer without drug wash solution (lane 3), two times wash solution with 
compound 2 (lane 5 and 6), and the resin (lane 4) were denatured in SDS sample buffer, 
and separated by SDS-PAGE. Lane 1 represents the molecular weight markers and lane 2 
is the whole cell lysate. Visualization of the separated proteins with silver stain showed 
the specific binding proteins with compound 2. 
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5.3.3. Identification of the binding proteins by LC-MS/MS 
 
Compound 2 binding proteins were separated by SDS/PAGE and collected by 
cutting the gel with the visible protein bands. After silver-staining agent was removed, 
the protein bands were subjected to tryptic digestion in situ. The resulting peptide mixture 
was identified with mass spectrometry. The molecular weight of the peptide mass 
fingerprint was used to identify the protein identity via Mascot database (Matrix Science 
Mascot, Boston, MA). The proteins with the best score (highest possibility) are listed in 
Table 5.1.  
 
Band a was identified to be the trypsin residue, which possible is the signal of the 
leftover trypsin in the digestion step, and band a itself did not give any countable signals. 
Bands b, c and f were keratin proteins with peptide mass fingerprint matching scores 
below 10%. These low binding, and without clear functions related to cell growth 
proteins are not listed in table 1. The major bands d and e were identified to be tubulin α 
and β, respectively. Band g was identified to be Hsp27. Both proteins are very critical for 
cancer cell proliferation (22).  
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Protein 
band 
Molecular 
weight(esti
mated 
based on 
the 
marker) 
Peptides (bold and underlined) matching with potential protein Percenta
ge of the 
matching  
Protein 
identity 
d 58KD MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK 
TIGGGDDSFN TFFSETGAGK HVPRAVFVDL EPTVIDEVRT 
GTYRQLFHPE QLITGKEDAA NYARGHYTI GKEIIDLVLD 
RIRKLADQCT GLQGFLVFHS FGGGTGSGFT SLLMERLSVD 
YGKKSKLEFS IYPAPQVSTA VVEPYNSILT THTTLEHSDC 
AFMVDNEAIY DICRRNLDIE RPTYTNLNRL ISQIVSSITA 
SLRFDGALNV DLTEFQTNLV PYPRIHFPLA TYAPVISAEK 
AYHEQLSVAE ITNACFEPAN QMVKCDPRHG KYMACCLLYR 
GDVVPKDVNA AIATIKTKRS IQFVDWCPTG FKVGINYQPP 
TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA 
KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV 
EGEGEEEGEE Y 
21% Bovin 
tubulin 
alpha chain 
e 55KD MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS 
DLQLDRISVY YNEATGGKYV PRAILVDLEP GTMDSVRSGP 
FGQIFRPDNF VFGQSGAGNN WAKGHYTEGA ELVDSVLDVV 
RKEAESCDCL QGFQLTHSLG GGTGSGMGTL LISKIREEYP 
DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY 
CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL 
RFPGQLNADL RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ 
YRALTVPELT QQVFDAKNMM AACDPRHGRY LTVAAVFRGR 
MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK TAVCDIPPRG 
LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG  
EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA 
EEEA 
23% Bovin 
Tubulin beta 
chain 
g 28KD MTERRVPFSL LRGPSWDPFR DWYPHSRLFD QAFGLPRLPE 
EWSQWLGGSS WPGYVRPLPP AAIESPAVAA PAYSRALSRQ 
LSSGVSEIRH TADRWRVSLD VNHFAPDELT VKTKDGVVEI 
TGKHEERQDE HGYISRCFTR KYTLPPGVDP TQVSSSLSPE 
GTLTVEAPMP KLATQSNEIT IPVTFESRAQ LGGPEAAKSD  
ETAAK 
25% Human heat 
shock 
protein 27 
 
       Table II.  Identify pull-down proteins by LC-MS/MS 
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5.3.4 Confirmation of protein identity with Western Blot 
 
To confirm the protein identity, we repeated the SDS-PAGE assay combined with 
western blot. As shown in Figure 5.4, the binding proteins were confirmed by using the 
corresponding antibodies. Tubulin and Hsp27 as molecular targets are new observation 
for the non-COX-2 active nimesulide anti-cancer derivatives. It was reported that tubulin 
has relatively strong interaction with Hsp27, and the two proteins could be co-
precipitated in the immunoprecipitation experiment (23). In our study, both proteins were 
pulled out by the probe, which could be due to the interaction between the two proteins. 
The probe might only bind either to tubulin or Hsp27, but the interaction between the two 
proteins could have caused them to both be retained by the probe.  
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Figure 5. 4 Protein identity confirmation with Western Blot. 
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5.3.5 Compound 2 binds directly with tubulin and Hsp27 
 
To rule out the possibility of co-precipitation, we used tubulin and Hsp27 pure 
proteins and our probe to repeat the binding experiments individually. The protein 
binding ability was determined with western analysis (Figure 5.5). After 5 times 
extensive washing with binding buffer, the extra proteins were all eluted and there were 
no proteins detected in the fifth elution solution. However, tubulin and Hsp27 were 
further eluted after 2 was added in the elution solution. The results indicated that both 
proteins could specifically bind to the probe and could be eluted with buffer containing 
compound 2, suggesting that compound 2 was the ligand for both proteins.  
Due to the structure similarity between compound 2 and Tubulin inhibitor 1, a colchicine 
domain binder, we speculated that compound 2 might also be a colchicine domain binder. 
To prove our hypothesis, we pre-incubated tubulin protein with an equivalent amount of 
colchicine for 1h, and then repeated the experiment. We found that the probe did not hold 
any tubulin protein (Figure 5.6), suggesting compound 2 and colchicine share same 
binding site and colchicine has higher binding affinity in the domain than compound 2. 
However, pre-incubation tubulin with Taxol did not affect the binding ability of the probe 
with the tubulin. These data are consistent with our hypothesis that compound 2 binds to 
the colchicine binding domain on tubulin. Pre-incubating tubulin with colchicine 
saturated the binding domain, and blocked the probe to attach to the protein, but Taxol 
with different binding domain did not affect the binding.     
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Figure 5. 5 Binding of biotinylated compound 2 with pure Hsp27, tubulin. 
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Figure 5. 6 Compound 2 binds to the colchicine binding domain on tubulin. 
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5.3.6 . Biological activity of compound 2 on tubulin 
 
 
5.3.6.1 In vivo tubulin polymerization assay 
 
We showed here that compound 2 binds to tubulin, however it is still not clear if 
the compound can interfere with tubulin function. Tubulin can be affected in two 
manners. Taxanes and epothilones stabilize tubulin polymerization, whereas vinca 
alkaloids, halichondrins and colchicine inhibit tubulin polymerization (24-27). Although 
binding differently, colchicine and vinca alkaloids show same mechanism of inhibition of 
tubulin. Compound 2, a relatively smaller and nonchiral molecule compared to the bulky 
and bearing multiple chiral centers natural product tubulin interfering agents, inhibited 
tubulin polymerization dose-dependently (Figure 5.7). Nocodazole, a well-known tubulin 
inhibitor, was used as a positive control for the assay. Compound 3, the first generation 
nimesulide anti-cancer derivative, showed moderate tubulin polymerization inhibitory 
activity.  
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Figure 5. 7 Effect of compound 2 on the organization of tubulin. 
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5.3.6.2 Compound 2 inhibits tubulin polymerization in cancer cells 
 
In addition, the tubulin polymerization inhibitory effect was observed in cancer 
cells (Figure 5.8). After 12h treatment with compound 2 at 0.5 µM and 1µM, the 
microtubules were disorganized and their density was significantly reduced in SKBR-3 
breast cancer cells. After 24h treatment, the effect was more pronounced. The results 
indicate that compound 2 could inhibit tubulin polymerization in both an assay with 
purified protein and in SKBR-3 cells. The results also are in agreement with the cell cycle 
arrest studies of compound 2 in previous studies (1).       
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Figure 5. 8 Effect of compound 2 on the organization of the microtubule 
cytoskeleton in cancer cell. 
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5.3.7 Biological activity of compound 2 on Hsp27 
 
Hsp27 is a chaperone of the sHsp (small heat shock protein) family. The common 
functions of sHsps are chaperone activity, thermotolerance, inhibition of apoptosis, 
regulation of cell development and cell differentiation. They are also partially involved in 
cell signal transduction (22, 28-31). Compound 2 showed significant anti-cancer activity 
in our previous studies (1). Tubulin inhibitory activity was responsible for the cancer cell 
toxic effect of the compound. Did Hsp27 play any role during the cell death since 
compound 2 bound to this protein? The phosphorylation of Hsp27 is the key step for 
Hsp27 to participate in the cell signal transduction process (23, 29). We checked the 
levels of phosphorylated Hsp27 and total Hsp27 in SKBR-3 breast cancer cells after 
compound 2 treatment (Figure 5.9). The compound significantly increased pHsp27 levels, 
which was similar to the response after tubulin inhibitor nocodazole treatment. Cells use 
pHsp27 as a protective molecule when any damage happened to the cells (22, 31). It is 
very common that cells express higher level of pHsp27 after being treated with cytotoxic 
agents (32). Compound 2 inhibited tubulin polymerization, and induced cell death, which 
very likely to promote the activation of pHsp27 in the cells. KRIBB3, an Hsp27 binder, 
also retained Hsp27 protein via its biotinylated probe in a protein pull down assay (33). It 
was used as a control and it significantly inhibited Hsp27 phosphorylation (Figure 5.9). It 
seemed that compound 2 showed a different manner to KRIBB3 regarding Hsp27 
inhibition, suggesting that compound 2 might bind to a different domain of Hsp27 and 
this domain did not involve in Hsp27 phosphorylation. It was also possible that the 
tubulin inhibitory activity of compound 2 dramatically induced Hsp27 phosphorylation 
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and overridden the direct Hsp27 inhibitory effect of the compound. Tubulin function was 
relatively easier to check with polymerization assay. However, it was difficult to 
elucidate whether Hsp27 was an anti-cancer target for compound 2. Besides Hsp27 
phosphorylation, the other downstream molecular and cellular consequences of Hsp27 
inhibition were not well defined. The tubulin inhibition could lead to Hsp27 
phosphorylation as indicated by pure tubulin inhibitor nocodazole in Figure 5.9, 
suggesting that tubulin function had a close correlation to Hsp27 function. It also made it 
difficult to solely investigate the Hsp27 effects of the dual targets compound 2. More 
medicinal chemistry effort is needed to develop more specific ligands and dissociate the 
two targets of compound 2. 
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Figure 5. 9 Effect of compound 2 on Hsp27. 
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5.4 Conclusion 
 
A class of new anti-cancer agents were developed based on the COX-2 inhibitor 
nimesulide as a lead compound (1).  To identify the molecular targets of the agents and 
elucidate the anti-cancer mechanism, we designed and synthesized the biotinylated 
nimesulide analog 2 as a probe. The proteins binding with the compound were isolated 
and subjected to mass spectrometric identification, and the most prevalent binding 
proteins were determined to be tubulin and Hsp27. Both proteins are very important for 
cancer cell proliferation. Further investigation revealed that the compound bound at 
colchicine binding domain on tubulin, and interrupted the polymerization of tubulin. 
However, the biological activity of compound 2 on Hsp27 was difficult to determine, 
because the tubulin inhibitory activity of compound 2 stimulated the activation of Hsp27 
signals. The direct Hsp27 inhibitory effects of compound 2 could be overridden by the 
tubulin inhibition consequences. Studies are now underway to further optimize 
compound 2 in order to generate more potent derivatives. In addition, more specific 
ligands, which have dissociated targets, i.e., pure tubulin inhibitor or pure Hsp27 
inhibitor, might be identified from the new compounds pool. The new sole ligands will 
allow us to further investigate the consequences of the Hsp27 inhibition.  
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